Lee, C., Yogesh Shah, A., Rao, A., Taylor, M. H., Di Simone, C., Hsieh, J. J., . . . Okpara, C. E. (2024). Lenvatinib plus Pembrolizumab Following Immune Checkpoint Inhibitor Treatment in Patients with Metastatic Clear Cell Renal Cell Carcinoma: Results from Study 111/KEYNOTE-146. European Urology, 86(5), 470-473. https://doi.org/10.1016/j.eururo.2024.05.003

Lee, Chung-Han, et al. "Lenvatinib Plus Pembrolizumab Following Immune Checkpoint Inhibitor Treatment in Patients with Metastatic Clear Cell Renal Cell Carcinoma: Results from Study 111/KEYNOTE-146." European Urology 86, no. 5 (2024): 470-473. https://doi.org/10.1016/j.eururo.2024.05.003.

Lee, Chung-Han, et al. "Lenvatinib Plus Pembrolizumab Following Immune Checkpoint Inhibitor Treatment in Patients with Metastatic Clear Cell Renal Cell Carcinoma: Results from Study 111/KEYNOTE-146." European Urology, vol. 86, no. 5, 2024, pp. 470-473, https://doi.org/10.1016/j.eururo.2024.05.003.